FREMONT, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, officially announced its Enhanced Small Particle (ESP™) Detection Option for its flagship Cytek Aurora™ and Cytek Northern Lights™ cell analysis systems. With this optional upgrade, these systems show superior sensitivity and resolution of subcellular materials, including extracellular vesicles (EVs), while maintaining high resolution and high parameter capabilities for ...

FREMONT, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, officially announced its Enhanced Small Particle (ESP™) Detection Option for its flagship Cytek Aurora™ and Cytek Northern Lights™ cell analysis systems. With this optional upgrade, these systems show superior sensitivity and resolution of subcellular materials, including extracellular vesicles (EVs), while maintaining high resolution and high parameter capabilities for ...

Cytek Biosciences, Inc. (NASDAQ:CTKB) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Paul Goodson - Investor Relations Wenbin Jiang - Chief Executive Officer William McCombe - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Jake Siewert - Goldman Sachs David Westenberg - Piper Sandler Noah Krozel - Raymond James Mason Carrico - Stephens Jacqueline Kisa - TD Cowen Operator Thank you for standing by. My name is Liz, and I'll be your conference o ...

Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to break-even earnings per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 80%. A quarter ago, it was expected that this company would post earnings of $0.03 per share when it actually produced earnings of $0.07, delivering a surprise of 133.33%.Over the last four quarters, the comp ...

Table of Contents SECURITIES AND EXCHANGE COMMISSION FORM 10-Q CYTEK BIOSCIENCES, INC. (Exact name of Registrant as specified in its Charter) _______________________________________________________ Registrant's telephone number, including area code: (877) 922-9835 _______________________________________________________ Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share CTKB The N ...

Cytek Biosciences Reports First Quarter 2024 Financial Results FREMONT, Calif., May 8, 2024 (GLOBE NEWSWIRE) — Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights • Total revenue was $44.9 million, representing a 21% increase over the corresponding period of 2023 • Organic revenue was $37.3 million, representing an increase of 11% compared to the fir ...

FREMONT, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, continues its commitment to advancing the cell analysis market by actively participating in key industry gatherings worldwide. The company's Full Spectrum Profiling™ (FSP™) technology, designed for streamlining workflows, expediting discoveries, and enhancing efficiency, will be prominently featured at both CYTO 2024 and AAI's IMMUNOLOGY2024. The company's distinctive approac ...

FREMONT, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, continues its commitment to advancing the cell analysis market by actively participating in key industry gatherings worldwide. The company's Full Spectrum Profiling™ (FSP™) technology, designed for streamlining workflows, expediting discoveries, and enhancing efficiency, will be prominently featured at both CYTO 2024 and AAI’s IMMUNOLOGY2024. The company's distinctive approa ...

FREMONT, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced it will report financial results for the first quarter 2024 after market close on Wednesday, May 8th, 2024. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" s ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Cytek Biosciences, Inc. (CTKB) .Cytek Biosciences currently has a ...